Development and implementation of participant safety plans for international research with stigmatised populations

Jeremy Sugarman, Mark Barnes, Scott Rose, Kostyantyn Dumchev, Riza Sarasvita, Ha Tran Viet, Oleksandr Zeziulin, Hepa Susami, Vivian Go, Irving Hoffman, William C. Miller

Research output: Contribution to journalArticle

Abstract

People who inject drugs with high-risk sharing practices have high rates of HIV transmission and face barriers to HIV care. Interventions to overcome these barriers are needed; however, stigmatisation of drug use and HIV infection leads to safety concerns during the planning and conduct of research on such interventions. In preparing to address concerns about safety and wellbeing of participants in an international research study, HIV Prevention Trials Network 074, we developed participant safety plans (PSPs) at each site to supplement local research ethics committee oversight, community engagement, and usual clinical trial procedures. The PSPs were informed by systematic local legal and policy assessments, and interviews with key stakeholders. After PSP refinement and implementation, we assessed social impacts at each study visit to ensure continued safety. Throughout the study, five participants reported a negative social impact, with three resulting from study participation. Future research with stigmatised populations should consider using and assessing this approach to enhance safety and welfare.

Original languageEnglish (US)
JournalThe Lancet HIV
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Safety
Research
Population
HIV
Social Change
Stereotyping
Research Ethics Committees
Pharmaceutical Preparations
HIV Infections
Clinical Trials
Interviews

ASJC Scopus subject areas

  • Epidemiology
  • Immunology
  • Infectious Diseases
  • Virology

Cite this

Development and implementation of participant safety plans for international research with stigmatised populations. / Sugarman, Jeremy; Barnes, Mark; Rose, Scott; Dumchev, Kostyantyn; Sarasvita, Riza; Viet, Ha Tran; Zeziulin, Oleksandr; Susami, Hepa; Go, Vivian; Hoffman, Irving; Miller, William C.

In: The Lancet HIV, 01.01.2018.

Research output: Contribution to journalArticle

Sugarman, J, Barnes, M, Rose, S, Dumchev, K, Sarasvita, R, Viet, HT, Zeziulin, O, Susami, H, Go, V, Hoffman, I & Miller, WC 2018, 'Development and implementation of participant safety plans for international research with stigmatised populations', The Lancet HIV. https://doi.org/10.1016/S2352-3018(18)30073-0
Sugarman, Jeremy ; Barnes, Mark ; Rose, Scott ; Dumchev, Kostyantyn ; Sarasvita, Riza ; Viet, Ha Tran ; Zeziulin, Oleksandr ; Susami, Hepa ; Go, Vivian ; Hoffman, Irving ; Miller, William C. / Development and implementation of participant safety plans for international research with stigmatised populations. In: The Lancet HIV. 2018.
@article{8643ee10187347b7a3d3850ae76a4992,
title = "Development and implementation of participant safety plans for international research with stigmatised populations",
abstract = "People who inject drugs with high-risk sharing practices have high rates of HIV transmission and face barriers to HIV care. Interventions to overcome these barriers are needed; however, stigmatisation of drug use and HIV infection leads to safety concerns during the planning and conduct of research on such interventions. In preparing to address concerns about safety and wellbeing of participants in an international research study, HIV Prevention Trials Network 074, we developed participant safety plans (PSPs) at each site to supplement local research ethics committee oversight, community engagement, and usual clinical trial procedures. The PSPs were informed by systematic local legal and policy assessments, and interviews with key stakeholders. After PSP refinement and implementation, we assessed social impacts at each study visit to ensure continued safety. Throughout the study, five participants reported a negative social impact, with three resulting from study participation. Future research with stigmatised populations should consider using and assessing this approach to enhance safety and welfare.",
author = "Jeremy Sugarman and Mark Barnes and Scott Rose and Kostyantyn Dumchev and Riza Sarasvita and Viet, {Ha Tran} and Oleksandr Zeziulin and Hepa Susami and Vivian Go and Irving Hoffman and Miller, {William C.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/S2352-3018(18)30073-0",
language = "English (US)",
journal = "The Lancet HIV",
issn = "2352-3018",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Development and implementation of participant safety plans for international research with stigmatised populations

AU - Sugarman, Jeremy

AU - Barnes, Mark

AU - Rose, Scott

AU - Dumchev, Kostyantyn

AU - Sarasvita, Riza

AU - Viet, Ha Tran

AU - Zeziulin, Oleksandr

AU - Susami, Hepa

AU - Go, Vivian

AU - Hoffman, Irving

AU - Miller, William C.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - People who inject drugs with high-risk sharing practices have high rates of HIV transmission and face barriers to HIV care. Interventions to overcome these barriers are needed; however, stigmatisation of drug use and HIV infection leads to safety concerns during the planning and conduct of research on such interventions. In preparing to address concerns about safety and wellbeing of participants in an international research study, HIV Prevention Trials Network 074, we developed participant safety plans (PSPs) at each site to supplement local research ethics committee oversight, community engagement, and usual clinical trial procedures. The PSPs were informed by systematic local legal and policy assessments, and interviews with key stakeholders. After PSP refinement and implementation, we assessed social impacts at each study visit to ensure continued safety. Throughout the study, five participants reported a negative social impact, with three resulting from study participation. Future research with stigmatised populations should consider using and assessing this approach to enhance safety and welfare.

AB - People who inject drugs with high-risk sharing practices have high rates of HIV transmission and face barriers to HIV care. Interventions to overcome these barriers are needed; however, stigmatisation of drug use and HIV infection leads to safety concerns during the planning and conduct of research on such interventions. In preparing to address concerns about safety and wellbeing of participants in an international research study, HIV Prevention Trials Network 074, we developed participant safety plans (PSPs) at each site to supplement local research ethics committee oversight, community engagement, and usual clinical trial procedures. The PSPs were informed by systematic local legal and policy assessments, and interviews with key stakeholders. After PSP refinement and implementation, we assessed social impacts at each study visit to ensure continued safety. Throughout the study, five participants reported a negative social impact, with three resulting from study participation. Future research with stigmatised populations should consider using and assessing this approach to enhance safety and welfare.

UR - http://www.scopus.com/inward/record.url?scp=85048956732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048956732&partnerID=8YFLogxK

U2 - 10.1016/S2352-3018(18)30073-0

DO - 10.1016/S2352-3018(18)30073-0

M3 - Article

C2 - 29950284

AN - SCOPUS:85048956732

JO - The Lancet HIV

JF - The Lancet HIV

SN - 2352-3018

ER -